The recent European approval of lutetium (177Lu) oxodotreotide increases treatment options for gastroenteropancreatic neuroendocrine tumors
Clinical outcomes in patients with baseline renal dysfunction in the NETTER-1 Study: 177Lu-DOTATATE (Lutathera®) vs high dose octreotide in progressive midgut neuroendocrine tumors
First Update on Overall Survival, Progression-free Survival, and Time-to-deterioration of Health-related Quality of Life from the NETTER-1 Study: 177Lu-DOTATATE (Lutathera®) vs high dose octreotide in progressive midgut neuroendocrine tumors
Overall Survival, Progression-Free Survival, and Quality of Life Updates from the NETTER-1 Study: 177Lu-DOTATATE (Lutathera®) vs High Dose Octreotide in Progressive Midgut Neuroendocrine Tumors
68Ga/177Lu-NeoBOMB1, a Novel Radiolabeled GRPR Antagonist for Theranostic Use in Oncology
Neuroendocrine Tumor Therapy: 177Lu-DOTATATE
Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With 177Lu-Dotatate in the Phase III NETTER-1 Trial
NeoBOMB1, a GRPR-Antagonist for Breast Cancer Theragnostics: First Results of a Preclinical Study with [67Ga]NeoBOMB1 in T-47D Cells and Tumor-Bearing Mice
Clinical History of the Theranostic Radioisotope Approach to Neuroendocrine Tumors and Other Types of Cancer: Historical Review Based on an Interview of Eric P. Krenning by Rachel Levine